Morgan Stanley raised the firm’s price target on Tandem Diabetes (TNDM) to $23 from $17 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care Appoints Sandra Beaver to Board
- Tandem Diabetes price target raised to $17 from $13 at Morgan Stanley
- Tandem Diabetes receives FDA clearance for use with Android smartphones
- Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth
- Tandem Diabetes price target raised to $16 from $15 at Stifel